-transparent.png){kind=logo}
Generation of an induced pluripotent stem cell (iPSC) line (INNDSUi007-A) from a patient with Kennedy disease. 2025
Bo Li, and
Yitong Yang, and
Yingxin Wang, and
Didi Shan, and
Jianing Li, and
Hongxu Wang, and
Xiaohan Sun, and
Yao Tang, and
Yichang Jiao, and
Xinbo Ji, and
Zexin Zhan, and
Bo Kong, and
Bo Gao, and
Yu Wang, and
Ping Sun, and
Fuchen Liu
Department of Neurosurgery, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
Abnormal trinucleotide CAG repeat expansions in exon 1 of the Androgen Receptor (AR) gene has been identified as the cause of Kennedy disease (KD). We generated and characterized a human induced pluripotent stem cell (iPSC) line from peripheral blood mononuclear cells (PBMC) of a patient with genetically confirmed KD. The pluripotency of these iPSCs was verified by the expression of several pluripotency markers at both RNA and protein levels, as well as their capability to differentiate into all three germ layers.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Bo Li, and
Yitong Yang, and
Yingxin Wang, and
Didi Shan, and
Jianing Li, and
Hongxu Wang, and
Xiaohan Sun, and
Yao Tang, and
Yichang Jiao, and
Xinbo Ji, and
Zexin Zhan, and
Bo Kong, and
Bo Gao, and
Yu Wang, and
Ping Sun, and
Fuchen Liu
March 2025,
Stem cell research,
Bo Li, and
Yitong Yang, and
Yingxin Wang, and
Didi Shan, and
Jianing Li, and
Hongxu Wang, and
Xiaohan Sun, and
Yao Tang, and
Yichang Jiao, and
Xinbo Ji, and
Zexin Zhan, and
Bo Kong, and
Bo Gao, and
Yu Wang, and
Ping Sun, and
Fuchen Liu
November 2016,
Stem cell research,
Bo Li, and
Yitong Yang, and
Yingxin Wang, and
Didi Shan, and
Jianing Li, and
Hongxu Wang, and
Xiaohan Sun, and
Yao Tang, and
Yichang Jiao, and
Xinbo Ji, and
Zexin Zhan, and
Bo Kong, and
Bo Gao, and
Yu Wang, and
Ping Sun, and
Fuchen Liu
October 2017,
Stem cell research,
Bo Li, and
Yitong Yang, and
Yingxin Wang, and
Didi Shan, and
Jianing Li, and
Hongxu Wang, and
Xiaohan Sun, and
Yao Tang, and
Yichang Jiao, and
Xinbo Ji, and
Zexin Zhan, and
Bo Kong, and
Bo Gao, and
Yu Wang, and
Ping Sun, and
Fuchen Liu
May 2022,
Stem cell research,
Bo Li, and
Yitong Yang, and
Yingxin Wang, and
Didi Shan, and
Jianing Li, and
Hongxu Wang, and
Xiaohan Sun, and
Yao Tang, and
Yichang Jiao, and
Xinbo Ji, and
Zexin Zhan, and
Bo Kong, and
Bo Gao, and
Yu Wang, and
Ping Sun, and
Fuchen Liu
December 2022,
Stem cell research,
Bo Li, and
Yitong Yang, and
Yingxin Wang, and
Didi Shan, and
Jianing Li, and
Hongxu Wang, and
Xiaohan Sun, and
Yao Tang, and
Yichang Jiao, and
Xinbo Ji, and
Zexin Zhan, and
Bo Kong, and
Bo Gao, and
Yu Wang, and
Ping Sun, and
Fuchen Liu
December 2024,
Stem cell research,
Bo Li, and
Yitong Yang, and
Yingxin Wang, and
Didi Shan, and
Jianing Li, and
Hongxu Wang, and
Xiaohan Sun, and
Yao Tang, and
Yichang Jiao, and
Xinbo Ji, and
Zexin Zhan, and
Bo Kong, and
Bo Gao, and
Yu Wang, and
Ping Sun, and
Fuchen Liu
October 2022,
Stem cell research,
Bo Li, and
Yitong Yang, and
Yingxin Wang, and
Didi Shan, and
Jianing Li, and
Hongxu Wang, and
Xiaohan Sun, and
Yao Tang, and
Yichang Jiao, and
Xinbo Ji, and
Zexin Zhan, and
Bo Kong, and
Bo Gao, and
Yu Wang, and
Ping Sun, and
Fuchen Liu
August 2025,
Stem cell research,
Bo Li, and
Yitong Yang, and
Yingxin Wang, and
Didi Shan, and
Jianing Li, and
Hongxu Wang, and
Xiaohan Sun, and
Yao Tang, and
Yichang Jiao, and
Xinbo Ji, and
Zexin Zhan, and
Bo Kong, and
Bo Gao, and
Yu Wang, and
Ping Sun, and
Fuchen Liu
December 2023,
Biomedicines,
Bo Li, and
Yitong Yang, and
Yingxin Wang, and
Didi Shan, and
Jianing Li, and
Hongxu Wang, and
Xiaohan Sun, and
Yao Tang, and
Yichang Jiao, and
Xinbo Ji, and
Zexin Zhan, and
Bo Kong, and
Bo Gao, and
Yu Wang, and
Ping Sun, and
Fuchen Liu
June 2023,
Stem cell research,
